Advertisement

Topics

PubMed Journals Articles About "Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia" RSS

10:04 EDT 16th July 2019 | BioPortfolio

Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia articles that have been published worldwide.

More Information about "Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia" on BioPortfolio

We have published hundreds of Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia news stories on BioPortfolio along with dozens of Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia Clinical Trials and PubMed Articles about Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia Companies in our database. You can also find out about relevant Testing The Addition Of An Anti-cancer Drug, Nedisertib, To The Usual Treatment (Mitoxantrone, Etoposide, And Cytarabine) For Relapsed Or Refractory Acute Myeloid Leukemia Drugs and Medications on this site too.

Showing "Testing Addition Anti cancer Drug Nedisertib Usual Treatment" PubMed Articles 1–25 of 60,000+

Statin therapy in the treatment of active cancer: A systematic review and meta-analysis of randomized controlled trials.

Preclinical evidence suggests statins may have anti-tumor properties. Large observational studies are also consistent with improved survival and cancer-specific outcomes among cancer patients on statins. We sought to evaluate the randomized controlled trials of statins in addition to usual anti-cancer therapy.


Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1.

LAG-3 is checkpoint inhibitor in cancer that coordinates the down regulation of the proliferation of antigen-specific lymphocytes. There is a great need to discover and develop new therapies focused on inhibiting the action of LAG-3 and consequently improving the immune response in the various types of cancer. Authors of patent US2018271940 propose a method to eradicate cancer that utilizes the combination of LAG-3Ig and anti-PD-1 or anti-PD-L1 antibodies. Areas covered: Patent US2018271940 describes a meth...

β-Asarone increases doxorubicin sensitivity by suppressing NF-κB signaling and abolishes doxorubicin-induced enrichment of stem-like population by destabilizing Bmi1.

Lymphoma is one of the most common hematologic malignancy. Drug resistance is the main obstacle faced in lymphoma treatment. Cancer stem cells are considered as the source of tumor recurrence, metastasis and drug resistance. The β-Asarone, a low-toxicity compound from the traditional medical herb , has been shown to act as an anti-cancer reagent in various cancer types. However, the anti-cancer activities of β-Asarone in lymphoma have not been shown.


The mechanism of anticancer action and potential clinical use of kaempferol in the treatment of breast cancer.

In the last century, natural compounds have achieved remarkable achievements in the treatment of tumors through chemotherapy. This inspired scientists to continuously explore anticancer agents from natural compounds. Kaempferol is an ordinary natural compound, the most common flavonoid, which is widely existed in vegetables and fruits. It has been reported to have various anticancer activities, including breast cancer, prostate cancer, bladder cancer, cervical cancer, colon cancer, liver cancer, lung cancer...

Antibody Therapeutics and Immunoregulation in Cancer and Autoimmune Disease.

Cancer and autoimmune disease are closely related, and many therapeutic antibodies are widely used in clinics for the treatment of both diseases. Among them, the anti-CD20 antibody has proven to be effective against both lymphoid malignancy and autoimmune disease. Moreover, immune checkpoint blockade using the anti-PD1/PD-L1/CTLA4 antibody has improved the prognosis of patients with refractory solid tumors. At the same time, however, over-enhancement of immunoreaction can induce autoimmune reaction. Althoug...

Quinolone hybrids and their anti-cancer activities: An overview.

The global pandemic of drug-sensitive cancers and the increasing threat from drug-resistant cancers make an urgent need to develop more effective anti-cancer candidates. Quinolone derivatives possess promising anti-cancer activity, and some of them have already been approved to treat cancers or under clinical trials. Hybridization of quinolone with other anti-cancer pharmacophores may provide more efficient anti-cancer candidates, so quinolone hybrids worth to be investigated. In this review, the recent adv...

Anti-Cancer Effects of Sulfasalazine and Vitamin E Succinate in MDA-MB 231 Triple-Negative Breast Cancer Cells.

Sulfasalazine (SSZ) displayed anti-cancer activities. Vitamin E succinate (VES) could inhibit cell growth in various cancer cells. However, chemical therapies were often not useful for triple-negative breast cancer cells (TNBCs) treatment. Here, this study investigated the anti-cancer effects and the mechanisms on TNBCs under combination treatment with SSZ and VES. Cell viability was analyzed by using the MTT assay. The HO levels were determined by using lucigenin-amplified chemiluminescence method. In add...

Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles.

Considerable development in the application of injectable drug delivery systems for cancer therapy has occurred in the last few decades. These improvements include liposomes, lipid nanoparticles (LNPs), and other nanoparticles with or without macromolecular conjugates. For example, liposomal doxorubicin modified by poly(ethylene glycol) (Doxil) was the first liposome with anti-cancer effects which was approved by the US Food and Drug Administration, whereas Abraxane (modified albumin nanoparticles loaded by...

Anti-cancer effect of Indanone-based thiazolyl hydrazone derivative on colon cancer cell lines.

Colorectal cancer is the third leading cause of cancer related deaths in the United States. Currently, Irinotecan, a topoisomerase I inhibitor, is an approved anti-cancer drug for the treatment of patients with advanced or recurrent colorectal cancer. Considering low response rate and events of high toxicity caused by irinotecan, we evaluated a series of thirteen thiazolyl hydrazone derivatives of 1-indanone for their potential antineoplastic activity and four compounds showed promising anti-cancer activity...

The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells.

The major obstacle in current cancer therapy is the existence of cancer stem cells (CSCs), which are responsible for therapeutic resistance and contribute to metastasis and recurrence. Identification of reliable biomarkers for diagnostic and therapeutic targets is necessary for drug development and cancer treatment. In this study, we identified that the antipsychotic chlorpromazine (CPZ) exhibited potent anti-breast cancer and anti-CSC capabilities. Treatment with CPZ suppressed stemness properties includin...

Effects of carbendazim and astaxanthin co-treatment on the proliferation of MCF-7 breast cancer cells.

There has been a controversy in the oncology field about the use of antioxidants along with chemotherapeutics in cancer treatment. This study aimed to investigate the effects of a potent antioxidant (astaxanthin) co-treatment with a promising anti-cancer drug (carbendazim), which is in phase I clinical trials, on MCF-7 breast cancer cell proliferation. MCF-7 cells were treated with carbendazim, astaxanthin, or their combinations and incubated for 24 h. After the incubation, each treatment group was evaluat...

Cationic block amphiphiles show anti-mitochondrial activity in multi-drug resistant breast cancer cells.

Currently, there are limited treatment options for multi-drug resistant breast cancer. Lipid modified, cationic peptides have the potential to reach the mitochondria, which are attractive targets for the treatment of multi-drug resistant (MDR) breast cancer; yet, little is known about their mitochondrial targeting and anti-cancer activity. Interestingly, lipid modified cationic peptides, typically used as gene transfection agents, exhibit similar structural features to mitochondrial targeted peptides. Using...

Chemotherapeutic agent 5-fluorouracil increases survival of SOD1 mouse model of ALS.

Amyotrophic lateral sclerosis (ALS) is a lethal motor neuron disease with no cure. Currently there are only two ALS drugs approved by the FDA, both with a limited therapeutic effect. In the search for drug candidates for ALS, we studied the effect of known stem cell mobilizing agents (treatment) and antimetabolite 5-fluorouracil (5-FU) (anti-treatment) in SOD1G93A model of ALS. Surprisingly, we found that anti-cancer drug 5-FU increases lifespan, delays the disease onset and improves motor performance in AL...

Home-based Anti-Tuberculosis Treatment Adverse Reactions (HATTAR) study: a protocol for a prospective observational study.

Tuberculosis (TB) continues to be an important public health problem throughout much of the world. Drug treatment is the only effective treatment method, but adverse drug events (ADEs) and adverse drug reactions (ADRs) can affect medication adherence. As the number of drug-resistant TB patients and the number of anti-TB drugs have increased, it is necessary to explore the risk factors for ADEs/ADRs to reduce their occurrence. This study aims to build a home-based anti-TB treatment cohort and to recognise th...

Effect of High-dose Vitamin C Combined With Anti-cancer Treatment on Breast Cancer Cells.

The anti-cancer effect of high doses of intravenous vitamin C (high-dose vitamin C) remains controversial despite growing evidence that high-dose vitamin C exerts anti-tumorigenic activity by increasing the amount of reactive oxygen species in cancer cells without meaningful toxicities. Therefore, this study attempted to demonstrate the in vitro anti-cancer activity of high-dose vitamin C in combination with conventional treatment in breast cancer.

α-Acid Glycoprotein Has the Potential to Serve as a Biomimetic Drug Delivery Carrier for Anti-Cancer Agents.

Nano-size plasma proteins could be used as a biomimetic drug delivery system (DDS) for cancer treatment when loaded with anticancer drugs, based on the fact that plasma proteins can serve as a source of nutrients for cancer cells. This prompted us to investigate the potential of α-acid glycoprotein (AGP) for this role, because it is a nano-size plasma protein and binds a variety of anti-cancer agents. Pharmacokinetic analyses indicated that AGP is distributed more extensively in tumor tissue than human ser...

Anti- antibodies attach to mouse cancer cell lines but not normal mouse lymphocytes.

is prevalent intracellular parasite and a cause of worldwide infection in the human population. An inhibitory effect of this parasite on cancer growth has been demonstrated in cell culture and animal models. To determine whether the anticancer activities of are associated with host immune response, in the current study the reactivity of anti- antiserum with the surface of cancer cell lines was investigated. Anti- antibodies were raised in rabbit and the reaction of this antiserum in comparison with other a...

Clinical Use of Epidermal Growth Factor Receptor Testing in Patients With Advanced Lung Cancer by Physicians: Survey of US and International Patterns.

Guidelines recommend testing for EGFR mutation at diagnosis of advanced non-small-cell lung cancer to guide treatment. Two surveys, 18 months apart, aimed to identify changes in EGFR mutation testing and treatment practices in non-small-cell lung cancer.

Mathematical Approach to Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.

Drug resistance is a major impediment to the success of cancer treatment. Resistance is typically thought to arise from random genetic mutations, after which mutated cells expand via Darwinian selection. However, recent experimental evidence suggests that progression to drug resistance need not occur randomly, but instead may be induced by the treatment itself via either genetic changes or epigenetic alterations. This relatively novel notion of resistance complicates the already challenging task of designin...

Higher Age Puts Lung-Cancer Patients at Risk for Not Receiving Anti-cancer Treatment.

We aimed to determine the demographic and epidemiologic variables that are associated with no treatment in lung cancer patients.

Advocacy for a New Oncology Research Paradigm: The Model of Bevacizumab in Triple-Negative Breast Cancer in a French Cohort Study.

Triple-negative breast cancer remains a disease with poor prognosis and few treatment options, due to the lack of therapeutic targets. Bevacizumab, the first anti-VEGF agent approved in the treatment of cancer, has demonstrated efficacy in breast cancer in combination with paclitaxel for the first-line treatment of HER2-negative metastatic breast cancer. Despite the fact that the benefit was particularly significant for triple-negative breast cancer with its approval in 2008 by the FDA, this decision was la...

The new management options for lung cancer in the immunotherapy era.

Lung cancer is the leading cause of cancer related deaths worldwide. Since the advent of immunotherapy, survival has significantly improved. Though encouraging treatment results, initially only some patients used to benefit significantly and specifically from immunotherapy administered alone. Recently, different combinations of immunotherapy treatments with cytotoxic chemotherapy and anti-angiogenic treatments were tested in order to improve the results. Six immunotherapy treatment strategies are currently ...

Carbon monoxide (CO)-Strengthened cooperative bioreductive anti-tumor therapy via mitochondrial exhaustion and hypoxia induction.

Bioreductive chemodrugs require hypoxic conditions to activate their anti-cancer efficacy. The insufficient and heterogeneous hypoxic condition in tumor tissues hurdles the therapeutic potency of bioreductive chemodrugs. We herein report a NIR light-triggered CO release system based on mesoporous Prussian blue nanoparticles (PB NPs) to enable cancer-selective hypoxia aggravation and hypoxia-responsive activation of bioreductive anti-cancer drug, tirapazamine (TPZ). Pentacarbonyl iron (Fe(CO)) was coupled to...

Integrating the drug, disulfiram into the vitamin E-TPGS-modified PEGylated nanostructured lipid carriers to synergize its repurposing for anti-cancer therapy of solid tumors.

The 'repurposed drug,' disulfiram (DSF), is an inexpensive FDA-approved anti-alcoholism drug with multi-target anti-cancer effect. However, the use of DSF in clinical settings remains limited due to its high instability in blood. In the present study, we created nanostructured lipid carriers (NLC) encapsulated DSF modified with D-α-tocopheryl polyethylene glycol 1000 succinate (vitamin E-TPGS). A spherical shape, superior drug encapsulation (80.7%), and decreased crystallinity of DSF were confirmed with re...

The anti-malarial drug artesunate causes cell cycle arrest and apoptosis of triple-negative MDA-MB-468 and HER2-enriched SK-BR-3 breast cancer cells.

Breast cancer is the most prevalent cancer diagnosis in women, with triple-negative and human epidermal growth factor 2 (HER2)-enriched advanced breast cancers having the poorest prognoses. The morbidity and mortality associated with advanced disease, as well as the emergence of multi-drug resistant variants, highlights the urgency to develop novel therapeutic agents. Artesunate (ART) is a semi-synthetic derivative of artemisinin from the Chinese herb sweet wormwood. ART is widely used in the treatment of m...


Advertisement
Quick Search
Advertisement
Advertisement